Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Hobberson Feb 12, 2015 11:39am
127 Views
Post# 23422237

RE:RE:RE:biosimilar market

RE:RE:RE:biosimilar market

Though I couldn't find any mention of BTI in Medimmune's annual report, I did find something on their website that may have been posted here before (see below). It may have been in the annual report, I just couldn't find it during a hasty review.

-------------------------

Alternative technologies to meet new challenges

  • Blood Brain Barrier (BBB) transport
    In many diseases, from pain to Alzheimer’s disease to multiple sclerosis, a number of well-validated targets are located behind the BBB. This significantly restricts their accessibility to peripherally administered biologics. Based on data from murine models, MedImmune has developed and deployed a number of transporter molecules that, when fused to a biologic, can carry the biologic across the BBB and elicit a central pharmacology response. This platform is now being exploited pre-clinically to develop antibody- and peptide-based therapeutics against a number of indications. We have collaborations with the National Research Council (NRC) of Canada as well as BiOasis (Toronto, Canada) in this area.

https://www.medimmune.com/research/technologies/alternate-technologies

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities